Supriya Lifescience Limited (SUPRIYA) - Total Assets
Based on the latest financial reports, Supriya Lifescience Limited (SUPRIYA) holds total assets worth Rs12.03 Billion INR (≈ $130.10 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Supriya Lifescience Limited (SUPRIYA) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Supriya Lifescience Limited - Total Assets Trend (2018–2025)
This chart illustrates how Supriya Lifescience Limited's total assets have evolved over time, based on quarterly financial data. See SUPRIYA net asset value for net asset value and shareholders' equity analysis.
Supriya Lifescience Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Supriya Lifescience Limited's total assets of Rs12.03 Billion consist of 39.3% current assets and 60.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 6.8% |
| Accounts Receivable | Rs1.35 Billion | 12.2% |
| Inventory | Rs1.18 Billion | 10.6% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs13.89 Million | 0.1% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Supriya Lifescience Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Supriya Lifescience Limited market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Supriya Lifescience Limited's current assets represent 39.3% of total assets in 2025, a decrease from 48.7% in 2018.
- Cash Position: Cash and equivalents constituted 6.8% of total assets in 2025, up from 1.1% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 12.2% of total assets.
Supriya Lifescience Limited Competitors by Total Assets
Key competitors of Supriya Lifescience Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
Supriya Lifescience Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.09 | 5.48 | 1.69 |
| Quick Ratio | 4.37 | 4.05 | 1.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs4.22 Billion | Rs3.38 Billion | Rs798.69 Million |
Supriya Lifescience Limited - Advanced Valuation Insights
This section examines the relationship between Supriya Lifescience Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.14 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 20.7% |
| Total Assets | Rs11.12 Billion |
| Market Capitalization | $728.78 Million USD |
Valuation Analysis
Below Book Valuation: The market values Supriya Lifescience Limited's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Supriya Lifescience Limited's assets grew by 20.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Supriya Lifescience Limited (2018–2025)
The table below shows the annual total assets of Supriya Lifescience Limited from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs11.12 Billion ≈ $120.29 Million |
+20.74% |
| 2024-03-31 | Rs9.21 Billion ≈ $99.63 Million |
+12.31% |
| 2023-03-31 | Rs8.20 Billion ≈ $88.71 Million |
+11.64% |
| 2022-03-31 | Rs7.35 Billion ≈ $79.46 Million |
+64.81% |
| 2021-03-31 | Rs4.46 Billion ≈ $48.21 Million |
+32.52% |
| 2020-03-31 | Rs3.36 Billion ≈ $36.38 Million |
+32.95% |
| 2019-03-31 | Rs2.53 Billion ≈ $27.37 Million |
+3.12% |
| 2018-03-31 | Rs2.45 Billion ≈ $26.54 Million |
-- |
About Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary… Read more